Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $28 from $24 and keeps a Buy rating on the shares. The firm said they raised their target on a higher price estimate and 55% probability of approval for zorevunersen in Dravet syndrome with a potential launch in 2028E.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Positive Outlook for Stoke Therapeutics: Buy Rating Reinforced by Phase 3 Trial Progress and Regulatory Engagement
- Buy Rating for Stoke Therapeutics: Promising Potential of Zorevunersen in Dravet Syndrome Treatment
- Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial Position
- Stoke Therapeutics Advances in RNA Medicine and Financial Growth
- Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics